CFM
VRTX icon

Catalyst Funds Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Catalyst Funds Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$431K Buy
965
+405
+72% +$189K 0.07% 275
2025
Q4 		$254K Buy
+560
New +$241K 0.06% 255
2024
Q4 		– Sell
-400
Closed -$186K – 1260
2024
Q3 		$186K Buy
+400
New +$192K 0.04% 308

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Catalyst Funds Management's VRTX Position: Q1 2026 in Review

Catalyst Funds Management increased its Vertex Pharmaceuticals (VRTX) stake by 72% in Q1 2026, buying an estimated $189K and bringing the position to 965 shares worth $431K. The position accounts for 0.07% of the portfolio, ranked #275.

Catalyst Funds Management first reported a position in VRTX in Q3 2024 and has held it in 3 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Catalyst Funds Management held 965 shares of Vertex Pharmaceuticals worth $431K as of Q1 2026.
  • Catalyst Funds Management bought 405 Vertex Pharmaceuticals shares in Q1 2026, an estimated $189K.
  • Vertex Pharmaceuticals made up 0.07% of Catalyst Funds Management's portfolio in Q1 2026, its #275 holding.
  • Catalyst Funds Management first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.